Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending
Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending
Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher Wednesday after the company reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of Alzheimer's disease dementia.
木薯科学公司（纳斯达克股票代码：SAVA）股价周三上涨，此前该公司公布了对拟治疗阿尔茨海默氏病痴呆的在研口服药物simufilam的为期两年的临床安全性研究的主要结果。
The Details:
细节：
The top-line results showed no decline in cognition scores in patients with mild Alzheimer's disease who received simufilam continuously for 24 months.
最重要的结果显示，持续接受simufilam治疗24个月的轻度阿尔茨海默氏病患者的认知分数没有下降。
"We're fighting Alzheimer's disease by testing simufilam, a new type of drug that has a completely different mechanism of action from monoclonal antibody drug treatments," said Remi Barbier, CEO of Cassava.
木薯首席执行官雷米·巴比尔说：“我们正在通过测试simufilam来对抗阿尔茨海默氏病，这是一种与单克隆抗体药物治疗完全不同的新型药物。”
"Stable ADAS-Cog scores over 2 years is clearly a desirable clinical outcome in Alzheimer's. Our data in mild patients may emphasize the importance of treating patients early in the disease."
“两年内稳定的ADAS-Cog评分显然是阿尔茨海默氏症理想的临床结果。我们对轻度患者的数据可能凸显了在疾病早期治疗患者的重要性。”
Cassava Sciences shares have grabbed the attention of retail investors and short-sellers alike. The stock is one of the top trending tickers on Stocktwits, and a remarkable 33.49% of available shares are being sold short.
木薯科学的股票吸引了散户投资者和卖空者的注意力。该股是Stocktwits上最热门的股票之一，有33.49％的可用股票被卖空。
Related News: What's Going On With Bitcoin Miners Marathon Digital and Riot Platforms Stock?
相关新闻：比特币矿工马拉松数字和防暴平台股票怎么了？
SAVA Price Action: According to Benzinga Pro, Cassava Sciences shares are up 2.2% at $24.18 at the time of publication.
SAVA价格走势：根据Benzinga Pro的数据，木薯科学的股价在发布时上涨2.2％，至24.18美元。
Image: Michal Jarmoluk from Pixabay
图片：来自 Pixabay 的 Michal Jarmoluk